The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SECuRE: A dose escalation/expansion study to assess the anti-tumor efficacy of 67Cu-SAR-bisPSMA in patients with metastatic castrate-resistant prostate cancer.
 
Geoffrey Johnson
Leadership - Green Clinic (I); Nucleus RadioPharma (Inst)
Consulting or Advisory Role - AstraZeneca (Inst); Blue Earth Diagnostics (Inst); Curium Pharma (Inst); MedTrace (Inst); MorphImmune (Inst); Novartis (Inst); Siemens Healthineers (Inst); Viewpoint Molecular Targeting (Inst); Viewpoint Molecular Targeting (Inst); Z-Alpha (Inst)
Research Funding - Clarity Pharmaceuticals (Inst); Clovis Oncology (Inst); MedTrace (Inst); Novartis (Inst); Pfizer (Inst); Viewpoint Molecular Targeting (Inst); Viewpoint Molecular Targeting (Inst)
Patents, Royalties, Other Intellectual Property - Patents on Radiopharmaceuticals; Patents on Radiopharmaceuticals (Inst)
 
Eva Lengyelova
Employment - Clarity Pharmaceuticals
Leadership - Clarity Pharmaceuticals
Stock and Other Ownership Interests - Clarity Pharmaceuticals
Travel, Accommodations, Expenses - Clarity Pharmaceuticals
 
Luke T. Nordquist
No Relationships to Disclose
 
Vikas Prasad
No Relationships to Disclose
 
Monique Anderson
Employment - Clarity Pharmaceuticals
Stock and Other Ownership Interests - Clarity Pharmaceuticals
Travel, Accommodations, Expenses - Clarity Pharmaceuticals
 
Othon Gervasio
Employment - Clarity Pharmaceuticals
Leadership - Clarity Pharmaceuticals
Stock and Other Ownership Interests - Clarity Pharmaceuticals
 
Michelle Parker
Employment - Clarity Pharmaceuticals
Leadership - Clarity Pharmaceuticals
Stock and Other Ownership Interests - Clarity Pharmaceuticals
 
Robert M. Miller
Employment - Clarity Pharmaceuticals; Hubro Therapeutics; Scancell Ltd.
Stock and Other Ownership Interests - Hubro Therapeutics (Inst)
Consulting or Advisory Role - Clarity Pharmaceuticals; Scancell Ltd.
Travel, Accommodations, Expenses - Hubro Therapeutics; Scancell Ltd.
 
A. Oliver Sartor
Stock and Other Ownership Interests - Abbvie; Cardinal Health; Clarity Pharmaceuticals; Convergent Therapeutics; Fusion Pharmaceuticals; Lilly; POINT Biopharma; PSMA Therapeutics; Ratiopharm; Telix Pharmaceuticals; United Health Group
Honoraria - Lantheus Medical Imaging
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; ARTbio; Astellas Pharma; AstraZeneca; Bavarian Nordic; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb; Clarity Pharmaceuticals; Clovis Oncology; Constellation Pharmaceuticals; Dendreon; EMD Serono; Fusion Pharmaceuticals; Hengrui Therapeutics; Isotopen Technologien; Janssen; MacroGenics; Medscape; Merck; Morphimmune; Myovant Sciences; Myriad Genetics; Noria Therapeutics; Northstar; Novartis; Noxopharm; Pfizer; Point Biopharma; Progenics; Ratio; Sanofi; Telix Pharmaceuticals; TEmpus; TeneoBio; Tessa Therapeutics; Theragnostics
Research Funding - Advanced Accelerator Applications (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Endocyte (Inst); InVitae (Inst); Janssen; Lantheus Medical Imaging (Inst); Merck (Inst); Progenics; Sanofi (Inst); SOTIO
Patents, Royalties, Other Intellectual Property - Koochekpour, Sartor AO, inventors. Saposin C and receptors as targets for treatment of benign and malignant disorders. US patent awarded January 23, 2007 (patent no. 7,166,691).
Expert Testimony - Sanofi
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Johnson & Johnson; Lantheus Medical Imaging; Progenics; Sanofi
 
Scott T. Tagawa
Stock and Other Ownership Interests - Convergent Therapeutics
Consulting or Advisory Role - 4D Pharma; Abbvie; AIkido Pharma; Amgen; Astellas Pharma; Bayer; Bicycle Therapeutics; Blue Earth Diagnostics; Clarity Pharmaceuticals; Clovis Oncology; Convergent Therapeutics; Daiichi Sankyo; Dendreon; Endocyte; Genentech; Genomic Health; Gilead Sciences; Hookipa Pharma; Immunomedics; Janssen; Karyopharm Therapeutics; Medivation; Merck; Myovant Sciences; Novartis; Pfizer; POINT Biopharma; QED Therapeutics; Regeneron; Sanofi; Seagen; Telix Pharmaceuticals; Tolmar; TransThera Biosciences
Research Funding - Abbvie (Inst); Ambrx (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clarity Pharmaceuticals (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); POINT Biopharma (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst)
Patents, Royalties, Other Intellectual Property - Patent Royalty from Immunomedics / Gilead
Travel, Accommodations, Expenses - Amgen; Immunomedics; Sanofi
(OPTIONAL) Uncompensated Relationships - Ambrx; ATLAB Pharma; Phosplatin Therapeutics